价格

LAG3-PD1

未知生产厂商

生成 AI 研报

专利

每项发明一条，涵盖美国、欧洲、PCT 与中国的同族专利。

PD1 AND/OR LAG3 BINDERS
EP 3377531 A2申请人: MERCK SHARP & DOHME优先权: 2015
CN
EP
US
WO
14 件公开
ANTI PD-1 AND ANTI-LAG3 ANTIBODIES FOR CANCER TREATMENT
EP 3458478 B1申请人: BOEHRINGER INGELHEIM INT优先权: 2016
CN
EP
US
WO
10 件公开
ANTI-LAG3 ANTIBODIES AND ANTIGEN-BINDING FRAGMENTS
- US 2017290914 A1
  申请人: MERCK SHARP & DOHME优先权: 2014
  US
  WO
  10 件公开
- US 11045547 B2
  申请人: MERCK SHARP & DOHME优先权: 2015
  CN
  US
  2 件公开
Bispecific antibodies specifically binding to PD1 and LAG3
US 11285207 B2申请人: HOFFMANN LA ROCHE优先权: 2017
CN
EP
US
WO
9 件公开
ARTIFICIAL ANTIGEN PRESENTING CELLS COMPRISING PROTEIN L FOR EXPANDING IMMUNE CELLS FOR IMMUNOTHERAPY
EP 3801570 A4申请人: H LEE MOFFITT CANCER CENTER & RES INSTITUTE INC优先权: 2018
EP
US
WO
5 件公开
COMBINATION THERAPY EMPLOYING A PD1-LAG3 BISPECIFIC ANTIBODY AND AN HLA-G T CELL BISPECIFIC ANTIBODY
EP 4680635 A1申请人: HOFFMANN LA ROCHE优先权: 2023
CN
EP
US
WO
4 件公开
IMMUNE REJECTION-RESISTANT ENGINEERED CELL
EP 4663762 A4申请人: HONGKONG BIOHENG BIOTECH LTD优先权: 2023
CN
EP
WO
3 件公开
Combination comprising immunostimulatory oligonucleotides
US 10487333 B2申请人: MOLOGEN AG优先权: 2015
CN
US
3 件公开
Therapeutic molecules that bind to LAG3 and PD1
US 11951172 B2申请人: CRESCENDO BIOLOGICS LTD优先权: 2018
CN
US
2 件公开
COMBINATION THERAPY EMPLOYING A PD1-LAG3 BISPECIFIC ANTIBODY AND A CD20 T CELL BISPECIFIC ANTIBODY
US 2024002546 A1申请人: HOFFMANN LA ROCHE优先权: 2021
CN
US
2 件公开

药物

LAG3-PD1

专利

ANTI-LAG3 ANTIBODIES AND ANTIGEN-BINDING FRAGMENTS